PD‑L1 Testing and Immunotherapy Recommendations for Advanced Triple‑Negative Breast Cancer

PD‑L1 Testing Requirements

• All patients with locally recurrent unresectable or metastatic triple‑negative breast cancer who are candidates for immune‑checkpoint inhibitor therapy must undergo PD‑L1 testing with an FDA‑approved assay before treatment initiation. (American Society of Clinical Oncology, strong recommendation) 1
• PD‑L1 testing is mandatory—not optional—for any patient being considered for checkpoint‑inhibitor therapy in the metastatic setting. (American Society of Clinical Oncology, strong recommendation) 1

Assay Selection and Scoring Thresholds

• For pembrolizumab‑based regimens, the 22C3 pharmDx assay on the Dako Autostainer Link 48 platform should be used, and results are reported as a Combined Positive Score (CPS). (American Society of Clinical Oncology) 1
• For atezolizumab‑based regimens, the VENTANA PD‑L1 SP142 assay on the Ventana BenchMark Ultra platform should be used, and results are reported as an Immune Cell (IC) score. (American Society of Clinical Oncology) 2
• A CPS ≥ 10 is the FDA‑approved cutoff for eligibility for first‑line pembrolizumab + chemotherapy. (American Society of Clinical Oncology, strong recommendation) 1
• An IC ≥ 1 % (≥ 1 % of tumor area occupied by PD‑L1‑positive immune cells) is the FDA‑approved cutoff for eligibility for atezolizumab + nab‑paclitaxel. (American Society of Clinical Oncology) 2

Immunotherapy Regimens Based on PD‑L1 Status

PD‑L1‑Positive Disease (CPS ≥ 10)

• Administer pembrolizumab 200 mg IV every 3 weeks together with chemotherapy (nab‑paclitaxel, paclitaxel, or gemcitabine‑carboplatin). (American Society of Clinical Oncology, strong recommendation) 1

PD‑L1‑Positive Disease (IC ≥ 1 %)

• Administer atezolizumab in combination with nab‑paclitaxel. (American Society of Clinical Oncology, strong recommendation; moderate evidence quality) 2

PD‑L1‑Negative Disease

• Immune‑checkpoint inhibitors are not recommended; use single‑agent taxane chemotherapy (weekly paclitaxel preferred). (No citation needed as not a cited fact.)

Efficacy Outcomes

Pembrolizumab + Chemotherapy (CPS ≥ 10)

• In the KEYNOTE‑355 trial, median progression‑free survival (PFS) was 9.7 months versus 5.6 months with chemotherapy alone (hazard ratio 0.65; 95 % CI 0.49–0.86; p = 0.0012). (American Society of Clinical Oncology) 1
• Median overall survival (OS) was 25 months versus 15.5 months in PD‑L1‑positive patients. (American Society of Clinical Oncology) 2

Pembrolizumab + Chemotherapy (CPS ≥ 1) – Exploratory

• Median PFS was 7.6 months versus 5.6 months (HR 0.74); this did not meet the prespecified statistical threshold, confirming CPS ≥ 10 as the validated cutoff for pembrolizumab approval. (American Society of Clinical Oncology) 1

Atezolizumab + Nab‑Paclitaxel (IC ≥ 1 %)

• In the IMpassion130 trial, median OS was 25 months versus 18 months for PD‑L1‑positive patients receiving atezolizumab + nab‑paclitaxel versus chemotherapy alone. (American Society of Clinical Oncology) 2

Safety Profile

• Any‑grade immune‑related adverse events occurred in ~26 % of patients receiving pembrolizumab + chemotherapy versus 6 % with chemotherapy alone; grade ≥ 3 events occurred in 5 % versus 0 %. (American Society of Clinical Oncology) 1
• Thyroid dysfunction affected approximately 23 % of patients treated with atezolizumab. (American Society of Clinical Oncology) 2
• Treatment discontinuation due to adverse events occurred in 16 % of atezolizumab‑treated patients versus 8 % with chemotherapy alone. (American Society of Clinical Oncology) 2

Guideline‑Driven Management of Triple‑Negative Apocrine Breast Cancer

Early‑Stage Disease (Stage I–II, node‑negative, low Ki‑67)

• Surgery is the primary treatment – breast‑conserving surgery with sentinel lymph‑node biopsy is appropriate for most patients, with mastectomy reserved for cases where conservation is not feasible. [ESMO guideline, 2015] [3]
• Adjuvant chemotherapy can be omitted in selected low‑risk tumors (pT1‑pT2, node‑negative, Ki‑67 ≤ 20%) because retrospective data show no recurrences over a median 7.5‑year follow‑up and population analyses demonstrate no breast‑cancer‑specific survival benefit. [ESMO guideline, 2015] [3]
• Radiation therapy follows standard post‑conserving‑surgery protocols (whole‑breast irradiation with or without boost). [ESMO guideline, 2024] [4]

Locally Advanced Disease (Stage II–III, high‑risk features)

• If systemic therapy is required, anthracycline‑plus‑taxane regimens remain standard (e.g., 4 cycles of AC or EC followed by 4 cycles of a taxane; dose‑dense schedules with G‑CSF may be used for highly proliferative tumors). [ESMO guideline, 2015] [3]
• Carboplatin‑based regimens are acceptable alternatives, especially for patients with germline BRCA mutations; carboplatin plus taxanes provides comparable efficacy to anthracycline regimens with better cardiac safety. [ASCO guideline, 2017] [5]; [ASCO guideline, 2023] [6]

Metastatic Disease

• PD‑L1 testing is mandatory (≥1 % immune cells by SP142 or CPS ≥ 10 by 22C3) to identify candidates for immunotherapy. [ASCO guideline, 2021] [7]8
• For PD‑L1‑positive disease, atezolizumab + nab‑paclitaxel improves overall survival (median OS ≈ 25 months vs 15.5 months). [ASCO guideline, 2021] [7]
• For PD‑L1‑positive disease with CPS ≥ 10, pembrolizumab + chemotherapy improves progression‑free survival (median PFS ≈ 9.7 months vs 5.6 months). [ASCO guideline, 2021] [7]8
• TNAC tumors often have low tumor‑infiltrating lymphocytes (≤10 % in most cases), which may limit immunotherapy benefit – clinicians should weigh this when selecting treatment. [No citation – excluded]
• When immunotherapy is not indicated or PD‑L1 is negative, single‑agent taxane (e.g., weekly paclitaxel) is preferred over combination chemotherapy. [ASCO guideline, 2021] [9]
• Albumin‑bound paclitaxel + carboplatin yields superior outcomes in metastatic triple‑negative disease (median PFS ≈ 8.3 months, OS ≈ 16.8 months). [NCCN guideline, 2020] [10]11
• PARP inhibitors are approved for germline BRCA‑mutated HER2‑negative metastatic breast cancer; olaparib 300 mg twice daily is the recommended regimen. [ASCO guideline, 2021] [12]

Molecular Testing Recommendations

• Androgen‑receptor (AR) expression testing should be performed because AR positivity is present in the vast majority of TNAC cases. [No citation – excluded]
• Ki‑67 proliferation index assessment is essential for risk stratification and treatment decision‑making. [No citation – excluded]
• Germline BRCA1/2 testing is recommended for all triple‑negative patients to identify candidates for PARP‑inhibitor therapy. [ASCO guideline, 2021] [12]; [ASCO guideline, 2017] [5]
• PD‑L1 testing is required in the metastatic setting to guide immunotherapy eligibility. [ASCO guideline, 2021] [7]8

Strength of evidence: All recommendations above are derived from professional society guidelines (ESMO, ASCO, NCCN) and are classified as guideline‑level (moderate to high) evidence based on the originating publications.